FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963794430> ?p ?o ?g. }

• W1963794430 endingPage "e52950" @default.
• W1963794430 startingPage "e52950" @default.
• W1963794430 abstract "Objectives To investigate the potential of nevirapine 200 mg once-daily regimen and evaluate the influence of patient characteristics on nevirapine concentrations. Methods This was a prospective, multicentre cohort study with 532 HIV-infected patients receiving nevirapine as a part of their initial antiretroviral therapy. Plasma samples were collected at trough or peak time at the end of week 2 (lead-in period) and week 4, 12, 24, 36, and 48 (steady-state period), and nevirapine concentrations were determined using a validated HPLC method. Potential influencing factors associated with nevirapine concentrations were evaluated using univariate and multivariate logistic regression. Results A total of 2348 nevirapine plasma concentrations were collected, including 1510 trough and 838 peak values. The median nevirapine trough and peak concentration during the lead-in period were 4.26 µg/mL (IQR 3.05–5.61) and 5.07 µg/mL (IQR 3.92–6.44) respectively, which both exceeded the recommended thresholds of nevirapine plasma concentrations. Baseline hepatic function had a moderate effect on median nevirapine trough concentrations at week 2 (4.25 µg/mL v.s. 4.86 µg/mL, for ALT <1.5×ULN and ≥1.5×ULN, respectively, P = 0.045). No significant difference was observed in median nevirapine trough concentration between lead-in and steady-state periods in patients with baseline ALT and AST level ≥1.5×ULN (P = 0.171, P = 0.769), which was different from the patients with ALT/AST level <1.5ULN. The median trough concentrations were significantly higher in HIV/HCV co-infected patients than those without HCV at week 48 (8.16 µg/mL v.s. 6.15 µg/mL, P = 0.004). Conclusions The 200 mg once-daily regimen of nevirapine might be comparable to twice-daily in plasma pharmacokinetics in Chinese population. Hepatic function prior to nevirapine treatment and HIV/HCV coinfection were significantly associated with nevirapine concentrations. Registration Clinicaltrial.gov ID: NCT00872417" @default.
• W1963794430 created "2016-06-24" @default.
• W1963794430 creator A5007617231 @default.
• W1963794430 creator A5012851930 @default.
• W1963794430 creator A5025546736 @default.
• W1963794430 creator A5025923651 @default.
• W1963794430 creator A5028609590 @default.
• W1963794430 creator A5031998757 @default.
• W1963794430 creator A5034868438 @default.
• W1963794430 creator A5044459845 @default.
• W1963794430 creator A5073267693 @default.
• W1963794430 creator A5075051424 @default.
• W1963794430 date "2013-01-24" @default.
• W1963794430 modified "2023-10-18" @default.
• W1963794430 title "Comparison of Nevirapine Plasma Concentrations between Lead-In and Steady-State Periods in Chinese HIV-Infected Patients" @default.
• W1963794430 cites W1517597567 @default.
• W1963794430 cites W1940770670 @default.
• W1963794430 cites W194602059 @default.
• W1963794430 cites W1963944716 @default.
• W1963794430 cites W1969791248 @default.
• W1963794430 cites W1981712752 @default.
• W1963794430 cites W1988363471 @default.
• W1963794430 cites W2004929843 @default.
• W1963794430 cites W2015229578 @default.
• W1963794430 cites W2048776156 @default.
• W1963794430 cites W2051030056 @default.
• W1963794430 cites W2054105441 @default.
• W1963794430 cites W2065405066 @default.
• W1963794430 cites W2068559235 @default.
• W1963794430 cites W2101191281 @default.
• W1963794430 cites W2123211579 @default.
• W1963794430 cites W2124431973 @default.
• W1963794430 cites W2124543441 @default.
• W1963794430 cites W2126506951 @default.
• W1963794430 cites W2135892517 @default.
• W1963794430 cites W2141776019 @default.
• W1963794430 cites W2151288869 @default.
• W1963794430 cites W2154703395 @default.
• W1963794430 cites W2159797384 @default.
• W1963794430 cites W2160557134 @default.
• W1963794430 cites W2164216849 @default.
• W1963794430 cites W2167794954 @default.
• W1963794430 cites W2406018938 @default.
• W1963794430 cites W4992121 @default.
• W1963794430 doi "https://doi.org/10.1371/journal.pone.0052950" @default.
• W1963794430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3554734" @default.
• W1963794430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23359265" @default.
• W1963794430 hasPublicationYear "2013" @default.
• W1963794430 type Work @default.
• W1963794430 sameAs 1963794430 @default.
• W1963794430 citedByCount "7" @default.
• W1963794430 countsByYear W19637944302014 @default.
• W1963794430 countsByYear W19637944302016 @default.
• W1963794430 countsByYear W19637944302017 @default.
• W1963794430 countsByYear W19637944302018 @default.
• W1963794430 countsByYear W19637944302019 @default.
• W1963794430 crossrefType "journal-article" @default.
• W1963794430 hasAuthorship W1963794430A5007617231 @default.
• W1963794430 hasAuthorship W1963794430A5012851930 @default.
• W1963794430 hasAuthorship W1963794430A5025546736 @default.
• W1963794430 hasAuthorship W1963794430A5025923651 @default.
• W1963794430 hasAuthorship W1963794430A5028609590 @default.
• W1963794430 hasAuthorship W1963794430A5031998757 @default.
• W1963794430 hasAuthorship W1963794430A5034868438 @default.
• W1963794430 hasAuthorship W1963794430A5044459845 @default.
• W1963794430 hasAuthorship W1963794430A5073267693 @default.
• W1963794430 hasAuthorship W1963794430A5075051424 @default.
• W1963794430 hasBestOaLocation W19637944301 @default.
• W1963794430 hasConcept C112705442 @default.
• W1963794430 hasConcept C126322002 @default.
• W1963794430 hasConcept C142462285 @default.
• W1963794430 hasConcept C144301174 @default.
• W1963794430 hasConcept C188816634 @default.
• W1963794430 hasConcept C203014093 @default.
• W1963794430 hasConcept C2779130552 @default.
• W1963794430 hasConcept C2781413609 @default.
• W1963794430 hasConcept C2910800852 @default.
• W1963794430 hasConcept C2993143319 @default.
• W1963794430 hasConcept C3013748606 @default.
• W1963794430 hasConcept C38180746 @default.
• W1963794430 hasConcept C71924100 @default.
• W1963794430 hasConcept C90924648 @default.
• W1963794430 hasConceptScore W1963794430C112705442 @default.
• W1963794430 hasConceptScore W1963794430C126322002 @default.
• W1963794430 hasConceptScore W1963794430C142462285 @default.
• W1963794430 hasConceptScore W1963794430C144301174 @default.
• W1963794430 hasConceptScore W1963794430C188816634 @default.
• W1963794430 hasConceptScore W1963794430C203014093 @default.
• W1963794430 hasConceptScore W1963794430C2779130552 @default.
• W1963794430 hasConceptScore W1963794430C2781413609 @default.
• W1963794430 hasConceptScore W1963794430C2910800852 @default.
• W1963794430 hasConceptScore W1963794430C2993143319 @default.
• W1963794430 hasConceptScore W1963794430C3013748606 @default.
• W1963794430 hasConceptScore W1963794430C38180746 @default.
• W1963794430 hasConceptScore W1963794430C71924100 @default.
• W1963794430 hasConceptScore W1963794430C90924648 @default.
• W1963794430 hasIssue "1" @default.
• W1963794430 hasLocation W19637944301 @default.

• next